ChromaDex Co. (NASDAQ:CDXC) Expected to Announce Earnings of -$0.09 Per Share


Share on StockTwits

Wall Street analysts forecast that ChromaDex Co. (NASDAQ:CDXC) will report earnings of ($0.09) per share for the current quarter, Zacks reports. Three analysts have made estimates for ChromaDex’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.09). ChromaDex also posted earnings per share of ($0.09) in the same quarter last year. The company is scheduled to report its next quarterly earnings report on Monday, May 10th.

According to Zacks, analysts expect that ChromaDex will report full-year earnings of ($0.30) per share for the current financial year, with EPS estimates ranging from ($0.42) to ($0.25). For the next financial year, analysts forecast that the company will report earnings of ($0.03) per share, with EPS estimates ranging from ($0.11) to $0.13. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover ChromaDex.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings data on Tuesday, March 9th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. ChromaDex had a negative return on equity of 100.14% and a negative net margin of 39.86%. The business had revenue of $15.45 million during the quarter, compared to analysts’ expectations of $15.40 million.

A number of research analysts have issued reports on CDXC shares. Oppenheimer started coverage on ChromaDex in a research note on Wednesday, March 10th. They issued a “buy” rating and a $9.00 target price for the company. B. Riley boosted their price target on ChromaDex from $7.00 to $18.00 and gave the company a “buy” rating in a report on Monday, March 8th. Zacks Investment Research upgraded ChromaDex from a “sell” rating to a “hold” rating in a report on Monday, March 29th. Finally, HC Wainwright boosted their price target on ChromaDex from $7.00 to $16.00 and gave the company a “buy” rating in a report on Monday, March 22nd.

In related news, Director Stephen A. Block sold 20,000 shares of the company’s stock in a transaction dated Tuesday, March 16th. The stock was sold at an average price of $13.17, for a total transaction of $263,400.00. Following the sale, the director now owns 49,167 shares in the company, valued at $647,529.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 12.92% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Wolff Wiese Magana LLC raised its stake in ChromaDex by 40.0% in the first quarter. Wolff Wiese Magana LLC now owns 7,000 shares of the company’s stock valued at $65,000 after buying an additional 2,000 shares during the period. Citigroup Inc. raised its stake in ChromaDex by 302.8% in the fourth quarter. Citigroup Inc. now owns 7,886 shares of the company’s stock valued at $38,000 after buying an additional 5,928 shares during the period. Principal Financial Group Inc. bought a new stake in ChromaDex in the fourth quarter valued at approximately $51,000. Ahrens Investment Partners LLC bought a new stake in ChromaDex in the fourth quarter valued at approximately $53,000. Finally, Hancock Whitney Corp acquired a new position in shares of ChromaDex in the fourth quarter valued at approximately $60,000. Hedge funds and other institutional investors own 24.74% of the company’s stock.

Shares of ChromaDex stock traded up $0.26 during trading on Thursday, reaching $7.88. 656,571 shares of the company were exchanged, compared to its average volume of 3,214,605. ChromaDex has a twelve month low of $3.82 and a twelve month high of $23.66. The business has a 50-day moving average price of $9.98 and a 200-day moving average price of $6.63. The firm has a market capitalization of $526.05 million, a price-to-earnings ratio of -20.74 and a beta of 1.49.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Featured Article: Diluted Earnings Per Share

Get a free copy of the Zacks research report on ChromaDex (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ChromaDex (NASDAQ:CDXC)

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.